Chinmay Jani, MD, highlights non-smoking risk factors, the impact of lung cancer on younger populations, and the value of comprehensive molecular testing.
|Videos|July 19, 2017
PD-L1 Testing in Lung Cancer
Author(s)Aaron S. Mansfield, MD
This video reviews the use of PD-L1 testing in selecting patients for frontline lung cancer treatment with pembrolizumab and examines which patients might not be appropriate for immunotherapy.
Advertisement
In this video, Aaron S. Mansfield, MD, of the Mayo Clinic in Rochester, Minnesota, reviews PD-L1 testing in selecting patients for frontline lung cancer treatment with pembrolizumab, and discusses which patients might not be appropriate for immunotherapy.
Mansfield spoke on this topic last month at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Advertisement
Related to this article
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the treatment of patients with NSCLC.
"As we combine more treatments…they have overlapping toxicities, and they may have the ability to synergize in a negative way," said Dwight H. Owen, MBBCh, MS.
Advertisement
Advertisement
Trending on CancerNetwork
1
Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer
2
CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma
3
Setting Up an HDR Brachytherapy Program Amid a National Decline
4
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
5